Feb. 6, 2003 — Ertapenem once daily was as efficacious and well tolerated for intra-abdominal infections as piperacillin/tazobactam four times daily, according to ...

Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive ...

Please provide your email address to receive an email when new articles are posted on . Emblaveo is the first monobactam/beta-lactamase inhibitor and antibiotic combination approved for this condition ...

For the first time since 2010, the Infectious Disease Society of America published new guidelines for treating complex abdominal infections. The revisions were prompted by “significant morbidity and ...

The FDA has approved aztreonam and avibactam (Emblaveo) in combination with metronidazole for adults who have limited or no alternative options for the treatment of complicated intra-abdominal ...

Background. When combined with ceftazidime, the novel non–β-lactam β-lactamase inhibitor avibactam provides a carbapenem alternative against multidrug-resistant infections. Efficacy and safety of ...

The Surgical Infection Society (SIS) presents new evidence-based guidelines for the management of intra-abdominal infection (IAI) in the peer-reviewed journal Surgical Infections. Click here to read ...

The U.S. Food and Drug Administration has approved the antibiotic meropenem for treating children less than 3 months old for abdominal infections, according to the National Institutes of Health.

Antibiotic stewardship requires using broad spectrum agents only when necessary in order to minimize spread of antibiotic resistance. The studies tested the impact on antibiotic prescribing of an ...

The Food and Drug Administration (FDA) has approved Emblaveo™ (aztreonam and avibactam), in combination with metronidazole, for patients 18 years and older who have limited or no alternative options ...